open access

Vol 22, No 3 (2017)
Original research articles
Published online: 2017-05-01
Submitted: 2016-08-01
Get Citation

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

Iván Henríquez López, David Parada, Pablo Gallardo, Marina Gascón, Arnau Besora, Karla Peña, Francesc Riu, Miquel Arquez Pianetta, Oscar Abuchaibe, Laura Torres Royò, Meritxell Arenas
DOI: 10.1016/j.rpor.2017.02.003
·
Rep Pract Oncol Radiother 2017;22(3):251-257.

open access

Vol 22, No 3 (2017)
Original research articles
Published online: 2017-05-01
Submitted: 2016-08-01

Abstract

Objectives

Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness.

The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT).

Methods

CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006.

CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed.

Results

Median CCP score was 0.9 (-0-1 – 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%.

BF and DSM were observed in 21% and 9%. Ki-67[[ce:hsp sp="0.25"/]]≥[[ce:hsp sp="0.25"/]]15% predicted BF (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76–71% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.83), 83–73% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.86), 89–85% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.84), and 94–78% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.66).

On univariate, high Ki-67 was correlated with BF (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.013), OS (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.023), DM (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.007), and DSM (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.01). On Cox MVA, high Ki-67 had a BF trend (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.063). High CCP score was not correlated with DSM.

Conclusions

High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.

Abstract

Objectives

Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness.

The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT).

Methods

CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006.

CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed.

Results

Median CCP score was 0.9 (-0-1 – 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%.

BF and DSM were observed in 21% and 9%. Ki-67[[ce:hsp sp="0.25"/]]≥[[ce:hsp sp="0.25"/]]15% predicted BF (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76–71% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.83), 83–73% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.86), 89–85% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.84), and 94–78% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.66).

On univariate, high Ki-67 was correlated with BF (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.013), OS (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.023), DM (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.007), and DSM (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.01). On Cox MVA, high Ki-67 had a BF trend (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.063). High CCP score was not correlated with DSM.

Conclusions

High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.

Get Citation

Keywords

pts; IHC; HE; CCP; ADT; FFbF; OS; GU; GI; CTCv3.0; CTV; DFS; DMFS; CSS; PCa; PSA; Gy; RT; Prostate cancer; Biomarkers; CCP genes; Ki-67

About this article
Title

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 22, No 3 (2017)

Pages

251-257

Published online

2017-05-01

DOI

10.1016/j.rpor.2017.02.003

Bibliographic record

Rep Pract Oncol Radiother 2017;22(3):251-257.

Keywords

pts
IHC
HE
CCP
ADT
FFbF
OS
GU
GI
CTCv3.0
CTV
DFS
DMFS
CSS
PCa
PSA
Gy
RT
Prostate cancer
Biomarkers
CCP genes
Ki-67

Authors

Iván Henríquez López
David Parada
Pablo Gallardo
Marina Gascón
Arnau Besora
Karla Peña
Francesc Riu
Miquel Arquez Pianetta
Oscar Abuchaibe
Laura Torres Royò
Meritxell Arenas

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl